Articles tagged "Hepatitis C"

2018 American Transplant Congress
Use of Hepatitis-C Treatments after Kidney Transplantation: Impact of the Direct-Acting Antiviral Era
K. Lentine, D. Axelrod,² R. Bloom,³ H. Xiao,¹ D. Segev,⁴ T. Alhamad,⁵ H. Randall,¹ R. Ouseph,¹ V. Dharnidharka,⁵ D. Brennan,⁴ N. Lam,⁶ A. Naik,⁷ G. Hess,⁸ B. Kaiske,⁹ M. Schnitzler.¹
¹Saint Louis U, St. Louis; ²Lahey, Burlington; ³U Penn, Philadelphia; ⁴Johns Hopkins, Baltimore; ⁵Washington U, St. Louis; ⁶U Alberta, Edmonton, Canada; ⁷U Michigan, Ann Arbor; ⁸Hennepin, Minneapolis; ⁹Symphony Health, Conshohocken.
Hepatitis C virus (HCV) infection in kidney transplant (KTx) donors or recipients has correlated with adverse outcomes, partly due to limited treatment options. Development of…
2018 American Transplant Congress
HCV Ab+/NAT- Organ Donors, and the Challenges of 'Eclipse Windows': Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
C. Wolfe, S. Tlusty, G. Vece, R. Sawyer, R. Bag, G. Berry, J. Bucio, L. Danziger-Isakov, D. Goldberg, C. Ho, D. Florescu, D. Klassen, R. La Hoz, K. Lilly, A. Mehta, M. Malinis, M. Nalesnik, N. Theodoropoulos, P. Wood, M. Michaels.
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: In 2017, CDC reported new hepatitis C (HCV) cases had tripled over 5 years, mainly due to intravenous drug use (IVDU). As the proportion…
2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
E. Agudelo,^1,2 I. Campos-Varela,³ N. Terrault.^1,2
¹Medicine, University of California San Francisco, San Francisco, CA; ²Surgery, University of California San Francisco, San Francisco, CA; ³Internal Medicine, Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…
2018 American Transplant Congress
Hidden Risk of Liver Transplantation for Nonalcoholic Steatohepatitis: A Propensity Score Matched Study
S. Nagai,¹ R. Schilke,¹ M. Safwan,¹ M. Rizzari,¹ K. Collins,¹ A. Yoshida,¹ M. Abouljoud,¹ D. Moonka.²
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI.
Aim: There is a recent shift in the number of liver transplants (LT) performed in patients with hepatitis C (HCV) to those with non-alcoholic steatohepatitis…
2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
A. Kwong,¹ A. Wall,² M. Melcher,² U. Wang,³ A. Ahmed,¹ K. Khush,³ A. Subramanian,³ J. Tan,³ P. Kwo.¹
¹Gastroenterology and Hepatology, Stanford University, Palo Alto, CA; ²Surgery, Stanford University, Palo Alto, CA; ³Stanford University, Palo Alto, CA.
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…
2018 American Transplant Congress
Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience
T. Chen,¹ M. Moaddab,¹ B. Pierce,¹ R. Ghobrial.²
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX; ²Department of Surgery, Houston Methodist Hospital, Houston, TX.
Background: Treatment of acute cellular rejection (ACR) in patients with orthotopic liver transplantation (OLT) secondary to hepatitis C virus (HCV) remains a major challenge due…
2017 American Transplant Congress
The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis.
Z. Guo, J. Gu, X. He, G. Chen.
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Previous studies have reported that ribavirin-free regimens are effective for treating chronic hepatitis C virus genotype 1 infection. However, the efficacy and safety of ribavirin-free…
2017 American Transplant Congress
Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.
P. Reese,¹ D. Goldberg,¹ A. Mussell,¹ M. McCauley,¹ D. Sawinski,¹ N. Molina,² R. Tomlin,² S. Doshi,¹ P. Abt,¹ E. Blumberg,¹ C. Thiessen,² S. Kulkarni,² G. Esnaola.²
¹UPENN, Philadelphia, PA; ²Yale, New Haven, CT
Background: New HCV drugs could reduce the risks of donor-derived HCV infection. However, it is unknown if HCV-negative (HCV-) ESRD patients would accept an HCV+…
2017 American Transplant Congress
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
J. Korula, T. Shah, E. Ranger, E. Barba, D. Vu, R. Naraghi.
Multi Transplant Organ Center, St Vincent Medical Center, Los Angeles, CA
Reports of efficacy of Direct Acting Antiviral drugs (DAA) > 90% in treatment of chronic HCV genotype 1, [GT1, 12 wk Sustained Viral Response (SVR12)]…
2017 American Transplant Congress
Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.
M. Nowicki,^1,2 H. Prince,² C. Chinchilla,² C. De Los Santos,² J. Trageser,³ L. Stocks.³
¹Mendez National Institute of Transplantation Foundation, Los Angeles, CA; ²VRL-Eurofins, Los Angeles, CA; ³Lifesharing OPO, San Diego, CA
Background Less than 0.2 % of initially NAT(+) upon retesting are reported as NAT negative. However, there is a concern that these results could be…